Bristol-Myers Squibb (BMY) Reports Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival in Phase 3 CheckMate -214 Trial
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) announced today results from the Phase 3 CheckMate -214 trial evaluating Opdivo (nivolumab) plus Yervoy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
